Nicolet Advisory Services LLC Boosts Stock Holdings in GSK plc (NYSE:GSK)

Nicolet Advisory Services LLC boosted its stake in GSK plc (NYSE:GSK) by 3.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,215 shares of the pharmaceutical company’s stock after purchasing an additional 430 shares during the quarter. Nicolet Advisory Services LLC’s holdings in GSK were worth $507,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in GSK. 1832 Asset Management L.P. lifted its position in shares of GSK by 9.1% in the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after buying an additional 257 shares in the last quarter. Boltwood Capital Management raised its holdings in shares of GSK by 2.5% during the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after acquiring an additional 270 shares in the last quarter. First Affirmative Financial Network boosted its position in shares of GSK by 4.7% during the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock valued at $245,000 after acquiring an additional 283 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock valued at $137,000 after purchasing an additional 303 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. increased its position in GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after purchasing an additional 323 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on GSK shares. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of GSK stock opened at $33.96 on Friday. The stock has a 50 day moving average price of $38.09 and a 200 day moving average price of $40.35. GSK plc has a 52-week low of $32.83 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The firm has a market capitalization of $70.38 billion, a P/E ratio of 22.05, a P/E/G ratio of 1.29 and a beta of 0.66.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.63%. The ex-dividend date is Friday, November 15th. GSK’s payout ratio is currently 99.35%.

Insider Activity

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.